Collectively, our data indicate that an unknown USP14-HSP90AA1-CYP2E1 axis contributes to NAFLD progression, and we propose that inhibition of USP14 may be an effective strategy for NASH treatment. Here, CYP2E1 is linked to metabolic dysfunction-associated steatotic liver disease.